RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:349

Fucosidosis

low confidenceDisorder

Also known as: Alpha-L-fucosidase deficiency

Publications

1,903

Trials

6

Interventional, condition-specific

Researchers

1,121

Distinct authors in sample

Gene link

FUCA1

Definitive

Readiness

5/6

Stages with a signal

Clinical definition (Orphanet)

A rare lysosomal storage disease characterized by widespread tissue buildup of glycolipids and oligosaccharides rich in fucose. Patients present with broad clinical characteristics such as , associated with psychomotor regression and bone abnormalities, visceromegaly, hyperhidrosis, and dermatological abnormalities.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

fucosidosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

5/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — FUCA1

  2. LiteraturePresent

    1,903 matched papers (936 in last 10 years) Source

  3. Phenotype characterisedPresent

    93 HPO annotations (e.g. Hemiplegia; Short stature; Flexion contracture) Source

  4. Animal modelPresent

    1 genotype model (Mus musculus) Source

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    6 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (FUCA1).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

93

Associated phenotypes · MONDO:0009254

  • Hemiplegia
  • Short stature
  • Flexion contracture
  • Seizure
  • Hypotonia

Showing 5 of 93 — open Monarch for the full list.

Animal models (Monarch / Alliance)

1

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,903

1,903 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,903 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

936 in the last 10 years · low confidence

Phrase hits: 947 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,121

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Taylor RM7 papers · 2016

    Faculty of Veterinary Science, University of Sydney, Camperdown, NSW, 2006, Australia. rosanne.taylor@sydney.edu.au.

    Papers in Europe PMC
  2. 02
    Kondagari GS6 papers · 2015

    Faculty of Veterinary Science, University of Sydney, NSW 2006, Australia.

    Papers in Europe PMC
  3. 03
    Fletcher JL5 papers · 2016

    Teh Faculty of Veterinary Science, The UNiversity of Sydney, Camperdown NSW, 2006, Autralia. jessica.fletcher@sydney.edu.au

    Papers in Europe PMC
  4. 04
    Stepien KM5 papers · 2025

    Salford Royal Organization, Northern Care Alliance NHS Foundation Trust, Adult Inherited Metabolic Diseases Department, Salford M6 8HD, UK.

    Papers in Europe PMC
  5. 05
    Lübke T4 papers · 2026

    Biochemistry I, Department of Chemistry, Bielefeld University, Bielefeld D-33615, Germany torben.luebke@uni-bielefeld.de.

    Papers in Europe PMC
  6. 06
    Vite CH4 papers · 2023

    Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.

    Papers in Europe PMC
  7. 07
    Williamson P4 papers · 2015

    Faculty of Veterinary Science, University of Sydney, Camperdown, NSW, 2006, Australia.

    Papers in Europe PMC
  8. 08
    Wood T4 papers · 2019

    Biochemical Genetics Laboratory, Greenwood Genetic Center, 106 Gregor Mendel Circle, Greenwood, SC 29646, USA.

    Papers in Europe PMC
  9. 09
    Amri Y3 papers · 2021

    Biochemistry Laboratory (LR 00SP03), Bechir Hamza Children's Hospital, Tunis, Tunisia.

    Papers in Europe PMC
  10. 10
    Boudabous H3 papers · 2021

    Pediatrics Department, La Rabta Hospital, Tunis, Tunisia.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

6

interventional trials for this specific condition

6 interventional trials matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026 · last trial check 28 July 2026

6 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.1th percentile).

low confidence · 90.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

6 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Fucosidosis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Fucosidosis" OR "Alpha-L-fucosidase deficiency") OR ("FUCA1" OR "FUCA1 syndrome" OR "FUCA1-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Fucosidosis" OR "Alpha-L-fucosidase deficiency"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 6 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1903) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T13:30:39.793Z